Claim Missing Document
Check
Articles

Found 2 Documents
Search

Immunomodulator Activity of the n-Hexane Extract of Binahong (Anredera cordifolia (Tenore.) Steenis) Leaves and Determination of Total Flavonoid Content Perdana Priya Haresmita; Cut Dewi Bunga; Luluc Rianawati; Nisa Fitriyani; Nurkhayati Nurkhayati; Bilqis Rahil Azizah; Adi Hermawansyah; Missya Putri Kurnia Pradani
Jurnal Tumbuhan Obat Indonesia Vol. 18 No. 2 (2025): December 2025
Publisher : Universitas Tidar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.31002/jtoi.v18i2.2802

Abstract

Binahong (Anredera cordifolia (Tenore.) Steenis) is one of the efficacious wild plants among us that has atherapeutic agent in the treatment of various diseases. This is influenced by secondary metabolite compoundsin the plant, especially flavonoids compounds. The purpose of this study was to determine theimmunomodulatory effect of n-hexane extract of Binahong leaves and determine total flavonoid contentcontained in Binahong leaves. The selected test animals were 25 mice divided into 5 different groups, eachgroup had 5 mice with a positive control, solvent control and a dose group of 25mg/kgBW, 50mg/kgBW and75mg/kgBW. One Way ANOVA test was used to compare immunomodulatory activity data with phagocytosiscapacity and phagocytosis index parameters. The research proved that n-hexane extract of Binahong leaves ata dose of 75mg/kgBW provided significant immunomodulatory activity with a significance value of p<0.05.The extract contains components of secondary metabolite flavonoid based on qualitative testing with colourreagents, namely FeCl3, NaOH and HCl with Magnesium (Mg) and the total flavonoid content was 3,370%calculated as quercetin. Keywords: Binahong, Immunomodulator, Macrophage, Phagocytosis, Total Flavonoid Content
Interventions on Costs and Survival Rates of Lung Cancer Patients Fitriana Yuliastuti; Nurfina Dian Kartikawati; Missya Putri Kurnia Pradani; Cut Dewi Bunga; Roshan Kumar Mahato
Borneo Journal of Pharmacy Vol. 8 No. 4 (2025): Borneo Journal of Pharmacy
Publisher : Institute for Research and Community Services Universitas Muhammadiyah Palangkaraya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33084/bjop.v8i4.10049

Abstract

Lung cancer is characterized by the uncontrolled growth of cells in the lung tissue, particularly in the lining of the respiratory tract. The disease has a high and alarming mortality rate, requiring prompt and appropriate management. This study aims to examine the costs and one-year survival rates of lung cancer patients at Dharmais Cancer Hospital. Data analysis was conducted in four stages: a retrospective observational study using secondary data from medical records, which described patient characteristics and factors affecting survival and treatment costs; analysis of survival curves by cancer stage and intervention; and testing differences in survival curves using the log-rank test. The results show that higher survival rates are often inversely proportional to shorter survival times, and vice versa. Stage 1 patients exhibited the most extended survival despite low survival rates for inpatients (48 months, 25%) and outpatients (53 months, 15%). Intervention types 4.00 (chemotherapy and radiotherapy) and 7.00 (chemotherapy, radiotherapy, and surgery) effectively extended survival, although associated survival rates remained low. The highest inpatient treatment costs were observed in stage 2 patients, while the highest annual outpatient costs were linked to surgical interventions, highlighting the difference between per-episode and cumulative annual expenditures.